Articles tagged "Hepatocellular carcinoma"

2019 American Transplant Congress
Prospective Multi-Regional Study of Down-Staging of Hepatocellular Carcinoma to within Milan Criteria before Liver Transplantation
N. Mehta¹, J. Guy², C. Frenette³, P. Tabrizian⁴, M. Hoteit⁵, R. Dhanasekaran⁶, J. Dodge¹, M. L. Holzner⁴, L. Frankul³, S. Florman⁴, N. Parikh⁷, F. Yao¹
¹UCSF, San Francisco, CA, ²CPMC, San Francisco, CA, ³Scripps Hospital, La Jolla, CA, ⁴Mt Sinai, New York, NY, ⁵U. Pennsylvania, Philadelphia, PA, ⁶Stanford, Palo Alto, CA, ⁷U. Michigan, Ann Arbor, MI
*Purpose: Recent studies from United Network of Organ Sharing (UNOS) Region 5 reported excellent outcomes after liver transplantation (LT) after successful down-staging in HCC patients…
2019 American Transplant Congress
Tumor Necrosis as a Result to Pre-Transplant Bridging Treatment for Hepatocellular Carcinoma and Its Effect on Post-Transplant Outcome
S. Radunz¹, A. Kirschner¹, J. M. Theysohn², C. Schotten³, T. Benkö¹
¹General, Visceral and Transplant Surgery, University Hospital Essen, Essen, Germany, ²Diagnostic and Interventional Radiology and Neurradiology, University Hospital Essen, Essen, Germany, ³Gastroenterology and Hepatology, University Hospital Essen, Essen, Germany
*Purpose: As a bridge to liver transplantation, locoregional treatments are commonly employed in hepatocellular carcinoma (HCC) patients to prevent tumor progression during waiting time. Objective…
2019 American Transplant Congress
Outcomes of Liver Transplantation for Mixed Hepatocellular-Cholangiocarcioma
M. Najjar¹, K. Bruestle¹, P. Jiang¹, S. Robbins-Juarez¹, R. Hwang¹, A. Mathur¹, E. C. Verna¹, A. Griesemer¹, B. Samstein¹, T. Kato¹, Y. M. Saenger¹, K. J. Halazun², J. C. Emond¹
¹Columbia University Medical Center, New York, NY, ²Weill Cornell Medicine, New York, NY
*Purpose: Mixed hepatocholangiocarcinomas (HCC-CCA) are rare tumors with both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) differentiations. They are usually associated with a worse prognosis than…
2019 American Transplant Congress
Resource Utilization in Hepatocellular Carcinoma Liver Transplantation before and after the Six Month Wait Time
J. Sokolich¹, W. McClellan², J. Buggs¹, E. Rogers¹, K. Barber¹, K. Cocuy¹, A. Kumar²
¹Tampa General Hospital, Tampa, FL, ²University of South Florida, Tampa, FL
*Purpose: The purpose of this study was to determine any difference in resource utilization since the implementation of the mandatory six month wait-time policy for…
2019 American Transplant Congress
Predicting HCC Recurrence Following Liver Transplant – A Machine Learning Approach
L. F. Lau¹, W. Nelson², A. Gorgen¹, L. Erdman², P. Abreu¹, A. Goldenberg², G. Sapisochin¹
¹Department of Surgery, University of Toronto, Toronto, ON, Canada, ²The Center for Computational Medicine, The Hospital for Sick Children, Toronto, ON, Canada
*Purpose: The liver transplant listing criteria for hepatocellular carcinoma (HCC) is controversial. Policies aim to prevent tumor recurrence but it has been difficult to encompass…
2019 American Transplant Congress
Hepatocellular Carcinoma in Fontan Liver Disease
V. Lamm¹, J. Wedd², C. Haydek², C. Obineme², A. Noll², H. Veeramachaneni², M. Muftah², R. Ford²
¹Internal Medicine, Emory, Atlanta, GA, ²Emory, Atlanta, GA
*Purpose: To add to the clinical characteristics and outcomes of hepatocellular carcinoma (HCC) in post Fontan operation patients and present, to the best of our…
2019 American Transplant Congress
Decreased Cancer Susceptibility in Tolerant Liver Transplant Recipients: Another Benefit of Tolerance?
M. P. Bhat¹, E. Pasini¹, C. Baciu¹, S. M. Kurian², J. Levitsky³
¹Multi-Organ Transplant, UHN, Toronto, ON, Canada, ²Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, ³Division of Gastroenterology & Hepatology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL
*Purpose: Long-term survival of transplant recipients is significantly impacted by malignancy. Induction of tolerance is feasible in a subset of liver transplant (LT) recipients. The…
2019 American Transplant Congress
Clinical Presentation After Hepatitis B Recurrence In Liver Transplant Patients
W. Lee, C. Cheng, T. Wu, Y. Wang, C. Lee, T. Wu, H. Chou, K. Chan
Chang-Gung Hospital, Taoyuan, Taiwan
*Purpose: Combination of anti-hepatitis B immunoglobulin and antiviral agents is the standard care for prophylaxis of hepatitis B virus (HBV) recurrence after liver transplantation. However,…
2019 American Transplant Congress
Spindle and Kinetochore Associated Complex Subunit 3 Promotes Tumor Growth by Regulating CDK2/p53 Phosphorylation in Hepatocellular Carcinoma
Y. Hou¹, Z. Wang², L. Wu³
¹Organ Transplant Center, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China, ²The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China, ³Organ transplant center, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
*Purpose: Spindle and kinetochore-related complex subunit 3 (SKA3) is a part of the spindle and kinetochore-related complexes, which are crucial for the proper timing of…
2019 American Transplant Congress
The Rapidly Aging Population of Liver Transplant Patients with Hepatocellular Carcinoma
J. B. Rubin, G. Cullaro, N. Mehta, J. C. Lai
Division of Gastroenterology & Hepatology, UCSF, San Francisco, CA
*Purpose: Hepatocellular carcinoma (HCC) is the fastest rising cause of cancer-related mortality in the US and a leading indication for liver transplant (LT). Direct acting…